Review: Recombinant human erythropoietin: novel strategies for neuroprotective/neuroregenerative treatment of multiple sclerosis
2008 | journal article
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Review: Recombinant human erythropoietin: novel strategies for neuroprotective/neuroregenerative treatment of multiple sclerosis
Bartels, C. ; Späte, K.; Krampe, H. & Ehrenreich, H. (2008)
Therapeutic Advances in Neurological Disorders, 1(3) pp. 193-206. DOI: https://doi.org/10.1177/1756285608098422
Documents & Media
Details
- Authors
- Bartels, Claudia ; Späte, Kira; Krampe, Henning ; Ehrenreich, Hannelore
- Abstract
- Treatment of multiple sclerosis (MS) is still unsatisfactory and essentially non-existing for the progressive course of the disease. Recombinant human erythropoietin (EPO) may be a promising neuroprotective/neuroregenerative treatment of MS. In the nervous system, EPO acts anti-apoptotic, antioxidative, anti-inflammatory, neurotrophic and plasticity-modulating. Beneficial effects have been shown in animal models of various neurological and psychiatric diseases, including different models of experimental autoimmune encephalomyelitis. EPO is also effective in human brain disease, as shown in double-blind placebo-controlled clinical studies on ischemic stroke and chronic schizophrenia. An exploratory study on chronic progressive MS yielded lasting improvement in motor and cognitive performance upon high-dose long-term EPO treatment.
- Issue Date
- 2008
- Journal
- Therapeutic Advances in Neurological Disorders
- Language
- English